Clinical Trial Update: REBEAT Resynchronisation and Beta-Blocker European Trial [Phase 4]

View source ↗

Summary

The Phase 4 REBEAT trial evaluating resynchronisation therapy in combination with beta-blocker treatment for heart failure has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure

Drugs mentioned

• beta-blocker therapy

Snippet

Sponsor: Guidant Corporation | Conditions: Heart Failure | Phase 4 | Status: TERMINATED